DAVID ALTSHULER - 17 May 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 May 2021
Net transactions value
-$17,093
Form type
4
Filing time
19 May 2021, 16:02:32 UTC
Next filing
16 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $1,722 -8 -0.02% $215.31 33,660 17 May 2021 Direct F1, F2, F3
transaction VRTX Common Stock Sale $12,113 -56 -0.17% $216.31 33,604 17 May 2021 Direct F1, F3, F4
transaction VRTX Common Stock Sale $3,257 -15 -0.04% $217.13 33,589 17 May 2021 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $215.31 (range $214.83 to $215.77).
F3 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $216.31 (range $215.83 to $216.80).
F5 Open market sales reported on this line occurred at a weighted average price of $217.13 (range $216.86 to $217.50).